



CURRICULUM VITAE MELAIU OMBRETTA

OMBRETTA MELAIU
Ombretta.Melaiu@uniroma2.it

WORK EXPERIENCES

February 2022– now:

- 1) RTDB at University of Rome Tor Vergata.
- 2) Affiliated researcher at Bambino Gesù Children's Hospital (Rome).

June 2020– January 2022:

Research Fellowship at Bambino Gesù Children's Hospital (Rome).

June 2017– May 2020:

- 1) RTDA at University of Pisa.
- 2) Affiliated researcher at Bambino Gesù Children's Hospital (Rome).

January 2017– May 2017:

Research Fellowship Fondazione Umberto Veronesi at Bambino Gesù Children's Hospital, Oncohematology Department. **Activities:** Dissecting the immune heterogeneity of neuroblastoma microenvironment to improve patient risk stratification and therapy.

May 2015– December 2016:

Research Fellowship at Bambino Gesù Children's Hospital, Oncohematology Department. **Activities:** Characterization of tumor-infiltrating T lymphocytes in therapy-resistant neuroblastoma patients.

April 2013–April 2015:

Research Fellowship at Pisa University, Department of Biology, Genetics; **Activities:** Study of new biomarkers for the clinical surveillance of workers previously exposed to asbestos.

April 2012–December 2012:

Visiting scientist at Imperial College, Oncology and Surgery Department., London, UK; **Activities:** Identification and characterization of genes involved in the malignant pleural mesothelioma.

EDUCATION

September 2013–November 2017:

Specialization in Pathology and Clinical Biochemistry, Roma Tor Vergata University. Title of thesis: "Significato clinico delle cellule immunitarie infiltranti tessuti di neuroblastoma. Mark: 50/50 with Honours. Tutors: Prof. Sergio Bernardini/Doriana Fruci.

January 2010–April 2013:

Research Doctorate School in Biological and Molecular Sciences, Pisa University. Title of thesis: "Identification and characterization of genes involved in the malignant pleural mesothelioma". Tutor: Prof. Landi.

October 2010–November 2010:

Qualification as Professional Biologist (Registration Number: 064338)

October 2007- October 2009:

Master degree in General Physiopatological Sciences - Biology 6/S; Pisa University; Title of thesis: "Cardio-metabolic biomarkers and myocardial infarction: study in an experimental animal model". Mark: 110/110 with Honours. Tutor: Dr. Giannessi.

October 2004- October 2007:

Bachelor of Biological and Molecular Science, Pisa University; Title of thesis: "Adiponectin: a new indicator of cardiovascular risk". Mark: 110/110 with Honours; Tutor: Dr. Giannessi.

LIST OF PUBLICATIONS

1. **Melaiu O***, Vanni G, Portarena I, Pistolese CA, Anemona L, Pomella S, Bei R, Buonomo OC, Roselli M, Mauriello A, Barillari G*. The combination of immune checkpoint blockade with tumor vessel normalization as a promising therapeutic strategy for breast cancer: an overview of preclinical and clinical studies. *Corresponding author. *Int J Mol Sci.* 2023 Feb 6;24(4):3226.
2. Pomella S†, Cassandri M†, **Melaiu O**, Marampon F, Gargari M, Campanella V, Rota R, Barillari G. DNA Damage Response Gene Signature as Potential Treatment Markers for Oral Squamous Cell Carcinoma. *Int J Mol Sci.* 2023 Jan 31;24(3):2673.
3. Lucarini V. #, **Melaiu O** #, D'Amico S, Pastorino F, Tempora P, Scarsella M, Pezzullo M, De Ninno A, D'Oria V, Cilli M, Emionite L, Infante P, Di Marcotullio L, De Ioris MA, Barillari G, Alaggio R, Businaro L, Ponzoni M, Locatelli F, Fruci D. Lucarini V. Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma. *J Exp Clin Cancer Res.* 2022 Nov 17;41(1):326. #, **Melaiu O** # **joint first position.**
4. Barillari G, **Melaiu O**, Gargari M, Pomella S, Bei R, Campanella V. The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview. *Int J Mol Sci.* 2022 Jul 28;23(15):8336.
5. D'Amico S, Tempora P, **Melaiu O**, Lucarini V, Cifaldi L, Locatelli F, Fruci D. Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy. *Front Immunol.* 2022 Jul 22;13:948297.
6. Vanni G, Pellicciaro M, Materazzo M, **Melaiu O**, Longo B, Cervelli V, Buonomo OC. Neoadjuvant Treatment as a Risk Factor for Variation of Upper Limb Lymph Node Drainage During Axillary Reverse Mapping in Breast Cancer: A Prospective Observational Study. *Anticancer Res.* 2022 Aug;42(8):3879-3888.
7. D'Amico S, D'Alicandro V, Compagnone M, Tempora P, Guida G, Romania P, Lucarini V, **Melaiu O**, Falco M, Algeri M, Pende D, Cifaldi L, Fruci D. ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function. *Front Immunol.* 2021 Nov 30;12:778103.
8. Bussola N*, Papa B*, **Melaiu O**, Castellano A, Fruci D, Jurman G. Quantification of the Immune Content in Neuroblastoma: Deep Learning and Topological Data Analysis in Digital Pathology. *Int J Mol Sci.* 2021 Aug 16;22(16):8804. *first authors.
9. Morani F, Bisceglia L, Rosini G, Mutti L, **Melaiu O**, Landi S, Gemignani F. Identification of Overexpressed Genes in Malignant Pleural Mesothelioma. *Int J Mol Sci.* 2021 Mar 8;22(5):2738.
10. D'Amico S, Tempora P, Lucarini V, **Melaiu O**, Gaspari S, Algeri M, Fruci D. ERAP1 and ERAP2 enzymes: a protective shield for RAS against COVID-19? *Int J Mol Sci.* 2021 Feb 8;22(4):1705.
11. Lucarini V†, **Melaiu O**†, Tempora P, D'Amico S, Locatelli F, Fruci D. Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment. *Cancers (Basel).* 2021 Jan 23;13(3):433. † = **first author equally contributed.**

12. Veneziani I, Infante P, Ferretti E, **Melaiu O**, Battistelli C, Lucarini V, Compagnone M, Nicoletti C, Castellano A, Petrini S, Ognibene M, Pezzolo A, Di Marcotullio L, Bei R, Moretta L, Pistoia V, Fruci D, Barnaba V, Locatelli F, Cifaldi L. Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors. *Cancer Immunol Res.* 2021 Feb;9(2):170-183.
13. Dell'Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, Paolicchi E, Corrado A, Cipollini M, **Melaiu O**, Giordano A, Luzzi L, Gemignani F, Landi S. Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma. *Invest New Drugs.* 2020 Dec 9. doi: 10.1007/s10637-020-01040-y.
14. **Melaiu O**, Chierici M, Lucarini V, Jurman G, Conti LA, De Vito R, Boldrini R, Cifaldi L, Castellano A, Furlanello C, Barnaba V, Locatelli F, Fruci D. Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. *Nat Commun.* 2020 Nov 25;11(1):5992.
15. **Melaiu O**, Macaudo A, Sainz J, Calvetti D, Facioni MS, Maccari G, Ter Horst R, Netea MG, Li Y, Grząsko N, Moreno V, Jurczynszyn A, Jerez A, Watek M, Varkonyi J, Garcia-Sanz R, Kruszewski M, Dudziński M, Kadar K, Jacobsen SEH, Mazur G, Andersen V, Rybicka M, Zawirska D, Rażny M, Zaucha JM, Ostrovsky O, Iskierka-Jazdzewska E, Reis RM, Stępień A, Beider K, Nagler A, Druzd-Sitek A, Marques H, Martínez-Lopez J, Lesueur F, Avet-Loiseau H, Vangsted AJ, Krawczyk-Kulis M, Butrym A, Jamroziak K, Dumontet C, Vogel U, Rymko M, Pelosini M, Subocz E, Szombath G, Sarasquete ME, Silvestri R, Morani F, Landi S, Campa D, Canzian F, Gemignani F. Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival. *Int J Cancer.* 2020 Nov 5. doi: 10.1002/ijc.33377.
16. **Melaiu O**, D'Amico S, Tempora P, Lucarini V, Fruci D. Impact of Natural Occurring ERAP1 Single Nucleotide Polymorphisms within miRNA-Binding Sites on HCMV Infection. *Int J Mol Sci.* 2020 Aug 15;21(16):5861. doi: 10.3390/ijms21165861.
17. Dell'Anno I, Barbarino M, Barone E, Giordano A, Luzzi L, Bottaro M, Migliore L, Agostini S, Melani A, **Melaiu O**, Catalano C, Cipollini M, Silvestri R, Corrado A, Gemignani F, Landi S. EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma. *Int J Mol Sci.* 2020 Jul 9;21(14):4856. doi: 10.3390/ijms21144856.
18. **Melaiu O**, Lucarini V, Giovannoni R, Fruci D, Gemignani F. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. *Semin Cancer Biol.* 2020 Jul 10;S1044-579X(20)30156-5. doi: 10.1016/j.semcancer.2020.07.001.
19. Gallerano D, Ciminati S, Grimaldi A, Piconese S, Cammarata I, Focaccetti C, Pacella I, Accapezzato D, Lancellotti F, Sacco L, Caronna R, **Melaiu O**, Fruci D, D'Oria V, Manzi E, Sagnotta A, Parrino C, Coletta D, Peruzzi G, Terenzi V, Battisti A, Cassoni A, Fadda MT, Brozzetti S, Fazzi K, Grazi GL, Valentini V, Chirletti P, Polimeni A, Barnaba V, Timperi E. Genetically driven CD39 expression shapes human tumor-infiltrating CD8+ T-cell functions. *Int J Cancer.* 2020 Nov 1;147(9):2597-2610.
20. Gemignani F, Romei C, Ciampi R, Corrado A, **Melaiu O**, Figlioli G, Bonotti A, Foddìs R, Cristaudo A, Pellegrini G, Vivaldi A, Cipollini M, Landi S, Elisei R. Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma. *Thyroid.* 2020 Mar 31. doi: 10.1089/thy.2019.0352
21. **Melaiu O**, Lucarini V, Cifaldi L, Fruci D. Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors. *Front Immunol.* 2020 Jan 21;10:3038.
22. Bufalieri F, Infante P, Bernardi F, Caimano M, Romania P, Moretti M, Severini L, Talbot J, **Melaiu O**, Tanori M, Di Magno L, Bellavia D, Puget S, De Smaele E, Canettieri G, Guardavaccaro D, Busino L, Peschiaroli A, Pazzaglia S, Giannini G, Melino G, Locatelli F, Gulino A, Ayrault O, Doriana Fruci D,* Di Marcotullio L. ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of β TrCP. *Nat Commun.* 2019 Jul 24;10(1):3304. doi: 10.1038/s41467-019-11093-0.

23. Cipollini M, Luisi S, Piomboni P, Luddi A, Landi D, **Melaiu O**, Figlioli G, Garritano S, Cappelli V, Viganò P, Gemignani F, Petraglia F, Landi S. Functional polymorphism within NUP210 encoding for nucleoporin GP210 is associated with the risk of endometriosis. *Fertil Steril*. 2019 Aug;112(2):343-352.e1.
24. Cammarata I, Martire C, Citroa A, Raimondo D, Fruci D, **Melaiu O**, D'Oria V, Carone C, Peruzzi G, Cerboni C, Santoni A, JSidney J, Sette A, Paroli M, Caccavale R, Milanetti E, Riminucci M, Timperi E, Piconese S, Manzo A, Montecucco C, Scrivo R, Valesini G, Cariani E, Barnaba V. Journal of autoimmunity. Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis. *J Autoimmun*. 2019 May;99:81-97.
25. Boldrini R*, De Pasquale MD*, **Melaiu O***, Chierici M, Jurman G, Benedetti MC, Salfi NC, Castellano A, Collini P, Furlanello C, Pistoia V, Cifaldi L, Terenziani M, Fruci D. Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors. *Oncoimmunology*. 2018 Dec 13;8(2):e1542245. ***Equally contribution.**
26. D'Alicandro V, Romania P, **Melaiu O**, Fruci D. Role of genetic variations on MHC class I antigen-processing genes in human cancer and viral-mediated diseases. *Mol Immunol*. 2018 Apr 3. pii: S0161-5890(18)30103-2.
27. **Melaiu O**, Gemignani F, Landi S. The genetic susceptibility in the development of malignant pleural mesothelioma. *J Thorac Dis*. 2018 Jan;10(Suppl 2):S246-S252.
28. Romania P, Cifaldi L, Pignoloni B, Starc N, D'Alicandro V, **Melaiu O**, Li Pira G, Giorda E, Carozzo R, Bergvall M, Bergström T, Alfredsson L, Olsson T, Kockum I, Seppälä I, Lehtimäki T, Hurme MA, Hengel H, Santoni A, Cerboni C, Locatelli F, D'Amato M, Fruci D. Identification of a Genetic Variation in ERAP1 Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated Immuno-evasion. *Cell Rep*. 2017 Jul 25;20(4):846-853.
29. Brandetti E, Veneziani I, **Melaiu O**, Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta L, Pistoia V, Locatelli F, Cifaldi L. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. *Oncoimmunology*. 2017 Apr 20;6(6):e1316439.
30. De Santi C*, **Melaiu O***, Bonotti A, Cascione L, Di Leva G, Foddìs R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. *Sci Rep*. 2017 Jun 9;7(1):3140. ***Equally contribution.**
31. **Melaiu O**, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddìs R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S. Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. *Genes Cancer*. 2017 Jan;8(1-2):438-452.
32. Bonotti A, Foddìs R, Landi S, **Melaiu O**, De Santi C, Giusti L, Donadio E, Ciregia F, Mazzoni MR, Lucacchini A, Bovenzi M, Comar M, Pantani E, Pistelli A, Cristaudo A. A Novel Panel of Serum Biomarkers for MPM Diagnosis. *Dis Markers*. 2017;2017:3510984.
33. De Santi C, Pucci P, Bonotti A, **Melaiu O**, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellè L, Vodicka P, Mutti L, Foddìs R, Cristaudo A, Gemignani F, Landi S. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. *Occup Environ Med*. 2017 Jun;74(6):456-463.
34. **Melaiu O**, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D'Alicandro V, Benedetti MC, Castellano A, Liu T, Furlanello C, Locatelli F, Fruci D. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. *Clin Cancer Res*. 2017 Aug 1;23(15):4462-4472.
35. Cipollini M, Figlioli G, Maccari G, Garritano S, De Santi C, **Melaiu O**, Barone E, Bambi F, Ermini S, Pellegrini G, Cristaudo A, Foddìs R, Bonotti A, Romei C, Vivaldi A, Agate L, Molinari

- E, Barale R, Forsti A, Hemminki K, Elisei R, Gemignani F, Landi S. Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma. *DNA Repair (Amst)*. 2016 May;41:27-31.
36. Figlioli G, Elisei R, Romei C, **Melaiu O**, Cipollini M, Bambi F, Chen B, Köhler A, Cristaudo A, Hemminki K, Gemignani F, Försti A, Landi S. A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2016 Apr;25(4):700-13.
37. Pellé L, Cipollini M, Tremmel R, Romei C, Figlioli G, Gemignani F, **Melaiu O**, De Santi C, Barone E, Elisei R, Seiser E, Innocenti F, Zanger UM, Landi S. Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma. *Arch Toxicol*. 2016 Dec;90(12):3099-3109.
38. **Melaiu O**, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddìs R, Lucchi M, Pellegrini S, Gemignani F, Landi S. Expression status of candidate genes in mesothelioma tissues and cell lines. *Mutat Res*. 2015 Jan;771:6-12.
39. Garritano S, De Santi C, Silvestri R, **Melaiu O**, Cipollini M, Barone E, Lucchi M, Barale R, Mutti L, Gemignani F, Bonotti A, Foddìs R, Cristaudo A, Landi S. A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people. *J Thorac Oncol*. 2014 Nov;9(11):1662-8.
40. **Melaiu O**, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddìs R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. *PLoS One*. 2014 Jan 21;9(1):e85935. doi: 10.1371/journal.pone.0085935. eCollection 2014. Erratum in: *PLoS One*. 2017 Jun 22;12(6):e0180317.
41. Cipollini M, Figlioli G, Garritano S, Bramante S, Maiorano L, Gnudi F, Cecchini A, De Paola F, Damicis L, Frixia T, Landi D, Cancemi L, De Santi C, **Melaiu O**, Foddìs R, Cristaudo A, Bonotti A, Romei C, Elisei R, Pellegrini G, Barale R, Gemignani F, Landi S. Risk of differentiated thyroid carcinoma and polymorphisms within the susceptibility cancer region 8q24. *Cancer Epidemiol Biomarkers Prev*. 2013 Nov;22(11):2121-5.
42. **Melaiu O**, Facioni MS, Cabiati M, Caruso R, Giannessi D, Landi S, Gemignani F, Del Ry S. Characterization of novel 3'untranslated regions and related polymorphisms of the gene NPPC, encoding for the C-type natriuretic peptide. *Peptides*. 2013 Jun;44:93-9. doi: 10.1016/j.peptides.2013.03.012. Epub 2013 Mar 28.
43. Stebbing J, Lit LC, Zhang H, Darrington RS, **Melaiu O**, Rudraraju B, Giamas G. The regulatory roles of phosphatases in cancer. *Oncogene*. 2014 Feb 20;33(8):939-53. doi: 10.1038/onc.2013.80. Epub 2013 Mar 18.
44. **Melaiu O**, Cristaudo A, Melissari E, Di Russo M, Bonotti A, Bruno R, Foddìs R, Gemignani F, Pellegrini S, Landi S. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. *Mutat Res*. 2012 Apr-Jun;750(2):132-40.
45. Caselli C, **Melaiu O**, Maltinti M, Del Ry S, Cabiati M, Prescimone T, Neglia D, Giannessi D. A methodological reappraisal of total and high molecular weight adiponectin determination in human peripheral circulation: comparison of four immunometric assays. *Clin Chem Lab Med*. 2010 Apr;48(4):561-8

ORAL AND POSTER PRESENTATIONS:

1) 17th international conference on computational intelligence methods for bioinformatics and biostatistics CIBB. February 2021: **Oral presentation:** Cellular and gene signatures of tumor-infiltrating dendritic cells and natural killer cells predict favorable clinical outcome of neuroblastoma. **Melaiu O.**

2) ANR webinars January 25- 26-27, 2021.

Oral presentation: Cellular and gene signatures of tumor-infiltrating dendritic cells and natural killer cells predict favorable clinical outcome of neuroblastoma. **Melaiu O.**

3) 4th ANNUAL MEETING AAC New technologies and strategies to fight cancer. Rome, 2019.

Poster: New strategies to reprogram dysfunctional tumor- infiltrating T cells in paediatric high-risk neuroblastoma.

Lucarini V, **Melaiu O**, De Ninno A, Businaro L, Fruci D.

4) Goodbye Flat Biology 2018. Berlin

Poster: "3D neuroblastoma cultures to define tumor-infiltrating T cell dysfunction and reprogramming".

Lucarini V, **Melaiu O**, Compagnone M, Ziccheddu G, Vinci M, Pistoia V, Cifaldi L, Fruci D

5) European Congress of Immunology 2018. Amsterdam

Poster: "Clinical relevance of intratumoral dendritic cells in neuroblastoma".

Melaiu O, Chierici M, Lucarini V, Compagnone M, Ziccheddu G, Jurman G, Boldrini R, Castellano A, Furlanello C, Locatelli F, Fruci D

6) ANR2018 Conference. 2018 San Francisco. USA

Poster: " Immune microenvironment in neuroblastoma: clinical and therapeutic relevance."

Melaiu O, Chierici M, Boldrini R, Jurman G, Castellano A, Furlanello C, Locatelli F, Fruci D.

7) Giornata Romana di Immunologia. 2017. Roma.

Oral Presentation: "Dissecting the tumor immune microenvironment in neuroblastoma"

Melaiu O.

8) 4th Neuroblastoma Research Symposium. 2015, Newcastle, UK.

Poster: "Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma."

Melaiu O, Mina M, Boldrini R, Pezzullo M, Furlanello C, Castellano A, Locatelli F, Fruci D.

9) IV Workshop AIEOP in lab. 2015, Napoli.

Oral Presentation: "Ruolo dei linfociti T infiltranti il tumore come potenziali marcatori prognostici e terapeutici in pazienti affetti da forme aggressive di neuroblastoma."

Melaiu O.

10) Fisv 2014, Pisa.

Poster: "Are MSLN, CFB and CCNO cancer genes of mesothelioma?"

Melaiu O, Barone E, Cipollini M, Figlioli G, Paolicchi E, Pellè L, De Santi C, Mutti L, Cristaudo A, Bonotti A, Foddis R, Gemignani G, Landi S. Premiato come miglior poster.

11) A.G.I. 2013 Cortona.

Poster: "Role of mesothelin and calretinin in malignant pleural mesothelioma."

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Pellegrini S, Melissari E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Lucchi M, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

12) Osservatorio Nazionale Amianto (ONA) Convegno giuridico-scientifico, 2013 Pisa.

Oral Presentation: "Le ultime acquisizioni scientifiche in materia di mesotelioma."

Melaiu O.

13) Società Italiana di Mutagenesi Ambientale (S.I.M.A.) 2013 Padova.

Oral presentation: "Comparative Genomic Hybridization Studies on Mesothelioma show a Parallel Fate of 1p21-1p22 and 9p21 Bands and a Chromosomally Stable Sub-Group." **Melaiu O.**

14) Fisv, 2012 Roma.

Poster: "Screening of MPM patients for activating somatic mutations within PDGFR-beta".

Melaiu O, Fontanini G, Costa B, Boldrini L, Mutti L, Sensi E, Bendinelli S, Bracci E, Lucchi M, Favoni R, Gemignani F, Landi S.

15) Imig, 2012 Boston.

Poster: “Screening of MPM patients for activating somatic mutations within PDGFRB”.

Melaiu O, Fontanini G, Costa B, Boldrini L, Mutti L, Sensi E, Bendinelli S, Bracci E, Lucchi M, Favoni R, Gemignani F, Landi S.

16) S.I.G.U., 2011 Milano.

Poster: “Identification and characterization of genes involved in the malignant pleural mesothelioma.”

Melaiu O, Cristaudo A, Bonotti A, Bruno R, Lucchi M, Foddìs R, Gemignani F, Landi S.

17) Società Italiana di Mutagenesi Ambientale (S.I.M.A.) 2011, Parma.

Oral presentation: “Identification and characterization of genes involved in the malignant pleural mesothelioma.”

Melaiu O.

18) EEMS, 2011 Barcellona.

Poster: “Analysis of potential target genes involved in carcinogenesis of malignant pleural mesothelioma.”

Melaiu O, Bruno R, Bonotti A, Gemignani F, Lucchi M, Foddìs R, Cristaudo A, Landi S.

AWARDS:

1) 2023: Research merit mention awarded by the Aiace Foundation

2) 2022: Award “Contributi premiali per i ricercatori e assegnisti di ricerca per rafforzare la condizione professionale e potenziare il sistema della ricerca del Lazio - Obiettivo di Policy 4 “Un’Europa più sociale”

3) Qualification for second class professor: From 31/01/2022 to 31/01/2031 SSD 06/N1 - Scienze Delle Professioni Sanitarie E Delle Tecnologie Mediche Applicate (ASN session 2021/2023);

From 31/01/2022 to 31/01/2031 SSD 06/A2 Patologia Generale E Patologia Clinica (ASN session 2021/2023);

From 31/01/2022 to 31/01/2031 SSD 05/I1 Genetica (ASN session 2021/2023).

4) 2021: Competition winner as Assistant Professor (RTDB) at Sapienza University of Rome, Rome, Italy, SSD 06/N1.

5) 2021: Fondazione Umberto Veronesi Award.

6) 2018: TRAVEL GRANT to European Congress of Immunology 2018 (Amsterdam).

7) 2014: Award for Best poster presentation at the XIII Congress of the Italian Federation of Life Sciences (Pisa Italy. Title: Are MSLN, CFB and CCNO cancer genes of mesothelioma?).

Roma, 09/03/2023

Umberto Melaiu